JP2022524435A5 - - Google Patents

Info

Publication number
JP2022524435A5
JP2022524435A5 JP2021554697A JP2021554697A JP2022524435A5 JP 2022524435 A5 JP2022524435 A5 JP 2022524435A5 JP 2021554697 A JP2021554697 A JP 2021554697A JP 2021554697 A JP2021554697 A JP 2021554697A JP 2022524435 A5 JP2022524435 A5 JP 2022524435A5
Authority
JP
Japan
Prior art keywords
rna
induced
modifications
target site
donor dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021554697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524435A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022056 external-priority patent/WO2020185867A1/en
Publication of JP2022524435A publication Critical patent/JP2022524435A/ja
Publication of JP2022524435A5 publication Critical patent/JP2022524435A5/ja
Priority to JP2024116841A priority Critical patent/JP2024133347A/ja
Pending legal-status Critical Current

Links

JP2021554697A 2019-03-11 2020-03-11 Ｒｎａ誘導型エンドヌクレアーゼを使用したｄｎａ構築物の組み込みプロセスの向上 Pending JP2022524435A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024116841A JP2024133347A (ja) 2019-03-11 2024-07-22 Ｒｎａ誘導型エンドヌクレアーゼを使用したｄｎａ構築物の組み込みプロセスの向上

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962816836P 2019-03-11 2019-03-11
US62/816,836 2019-03-11
US201962901735P 2019-09-17 2019-09-17
US62/901,735 2019-09-17
PCT/US2020/022056 WO2020185867A1 (en) 2019-03-11 2020-03-11 Improved process for integration of dna constructs using rna-guided endonucleases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024116841A Division JP2024133347A (ja) 2019-03-11 2024-07-22 Ｒｎａ誘導型エンドヌクレアーゼを使用したｄｎａ構築物の組み込みプロセスの向上

Publications (2)

Publication Number Publication Date
JP2022524435A JP2022524435A (ja) 2022-05-02
JP2022524435A5 true JP2022524435A5 (enExample) 2023-03-15

Family

ID=70190148

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021554697A Pending JP2022524435A (ja) 2019-03-11 2020-03-11 Ｒｎａ誘導型エンドヌクレアーゼを使用したｄｎａ構築物の組み込みプロセスの向上
JP2024116841A Pending JP2024133347A (ja) 2019-03-11 2024-07-22 Ｒｎａ誘導型エンドヌクレアーゼを使用したｄｎａ構築物の組み込みプロセスの向上

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024116841A Pending JP2024133347A (ja) 2019-03-11 2024-07-22 Ｒｎａ誘導型エンドヌクレアーゼを使用したｄｎａ構築物の組み込みプロセスの向上

Country Status (11)

Country Link
US (1) US20220145333A1 (enExample)
EP (1) EP3938510A1 (enExample)
JP (2) JP2022524435A (enExample)
KR (1) KR20210149734A (enExample)
CN (1) CN113825834A (enExample)
AU (1) AU2020239050A1 (enExample)
CA (1) CA3133226A1 (enExample)
IL (1) IL286244A (enExample)
MX (1) MX2021010938A (enExample)
SG (1) SG11202109972QA (enExample)
WO (1) WO2020185867A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139345A1 (en) 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
WO2022015956A1 (en) 2020-07-15 2022-01-20 Sorrento Therapeutics, Inc. Improved process for dna integration using rna-guided endonucleases
WO2022061115A1 (en) * 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
JP2024515936A (ja) * 2021-03-19 2024-04-11 メタゲノミ，インク． Ｃａｓ酵素を用いたマルチプレックス編集
WO2022214522A2 (en) * 2021-04-07 2022-10-13 Astrazeneca Ab Compositions and methods for site-specific modification
EP4370676A2 (en) * 2021-06-18 2024-05-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
WO2023097236A1 (en) * 2021-11-24 2023-06-01 The Rockefeller University Compositions and methods for generating immunoglobulin knock-in mice
CN115851591A (zh) * 2022-11-30 2023-03-28 山东博群生物技术有限公司 细胞因子刺激剂及诱导淋巴细胞产生细胞因子的方法
WO2026020171A2 (en) 2024-07-19 2026-01-22 Aera Therapeutics, Inc. Chimeric antigen receptor constructs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
CA2720903C (en) * 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2015089427A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
US9879283B2 (en) * 2014-10-09 2018-01-30 Life Technologies Corporation CRISPR oligonucleotides and gene editing
CA2986310A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP4144844B1 (en) * 2015-10-12 2025-09-10 DuPont US Holding, LLC Protected dna templates for gene modification and increased homologous recombination in cells and methods of use
MX2019003674A (es) 2016-09-30 2021-01-08 Univ California Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
WO2018175636A2 (en) * 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
WO2018232356A1 (en) * 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
AU2018313167A1 (en) * 2017-08-08 2020-02-27 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
AU2019231315A1 (en) 2018-03-09 2020-09-17 Vivasor, Inc. Dimeric antigen receptors (DAR)

Similar Documents

Publication Publication Date Title
JP2022524435A5 (enExample)
JP2022521787A5 (enExample)
JP2024174943A5 (enExample)
US11884915B2 (en) Guide RNAs with chemical modification for prime editing
JP2022523302A (ja) アッシャー症候群の処置のためのｒｎａ編集オリゴヌクレオチド
JP2023504264A5 (enExample)
RU2017130143A (ru) Гибридные днк/рнк-полинукдеотиды crispr и способы
CN107787367A (zh) 用于crispr/cas介导的基因调控的化学修饰的引导rna
US20120015821A1 (en) Methods of Generating Gene Specific Libraries
WO2016161380A1 (en) Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
WO2017040511A1 (en) Compounds and methods for crispr/cas-based genome editing by homologous recombination
CA2968336A1 (en) Construct for site directed editing of an adenosine nucleotide in target rna
WO2016094845A3 (en) Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
CA3025523A1 (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules
JP2020524998A5 (enExample)
CN102203273A (zh) 生成基因特异性的文库的方法
WO2015089053A1 (en) Long nucleic acid sequences containing variable regions
RU2020100919A (ru) СПОСОБ НОКАУТИРОВАНИЯ ГЕНА-МИШЕНИ В T-КЛЕТКЕ IN VITRO И crRNA, ПРИМЕНЯЕМАЯ В ДАННОМ СПОСОБЕ
JP7762651B2 (ja) 修飾二重鎖ドナー鋳型
JP2024533448A (ja) 化学修飾を有するガイドｒｎａを使用する方法
Layden et al. Alternate trans splicing in Trypanosoma equiperdum: implications for splice site selection
US20240309396A1 (en) Compositions and methods for improved gene editing
Moss History and development of molecular biology
US12522857B2 (en) Compositions and methods of targeted nucleic acid enrichment by loop adapter protection and exonuclease digestion
KR102515727B1 (ko) 중첩된 가이드핵산을 이용한 표적 핵산에 특정 핵산 서열을 삽입하기 위한 조성물 및 방법